Biotech Stock Movers (PPHM, YMI, HEB, DVAX, ACAD)
NEW YORK, September 18, 2012 (MESHPRESS) – Beststocksdaily.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-
Peregrine Pharmaceuticals(NASDAQ:PPHM) shares jumped 5.81% and closed at $4.81 in the last trading session. The company announced that its management team will be meeting with investors to review its portfolio of novel drug candidates and the recent positive clinical data from the company’s Phase II trial in second-line non-small cell lung cancer, as part of the 3rd Annual Credit Suisse 2012 Small & Mid Cap Conference. The event will be held at The New York Palace Hotel in New York, New York, with management conducting meetings on Friday, September 21, 2012.
Additionally, equities research analysts at Roth Capital increased their price target on shares of Peregrine Pharmaceuticals from $5.00 to $9.00 in a research note issued to investors on Sept. 10.
Can PPHM Continue To Move Higher? Find Out Here
YM BioSciences Inc. (USA)(NYSEAMEX:YMI) shares climbed 5.06% and closed at $1.87 in the previous trading session. The 52 week trading range for the company is $1.03 – $2.46. The shares of the company declined 6% in the last one year. The company is a drug development company advancing a diverse portfolio of hematology and cancer-related products.
Can YMI Extend Rally? Find Out Here
Hemispherx BioPharma, Inc(NYSEAMEX:HEB) shares fell 4.79% and closed at $0.765 in yesterday’s session. The 52 week trading range for the company is $0.17 – $0.95. The shares of the company soared 125% in the last one year. The company is a specialty pharmaceutical engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders.
Can HEB Recover After The Recent fall? Find Out Here
Dynavax Technologies Corporation (NASDAQ:DVAX) stock jumped 4.84% and closed at $4.77 in the last trading session. The 52 week trading range for the company is $1.75 – $5.34. The shares of the company soared 95% in the last one year. The company is a clinical-stage biopharmaceutical company, discovers and develops products to prevent and treat infectious and inflammatory diseases.
How Should Investors Trade DVAX Now? Find Out Here
ACADIA Pharmaceuticals Inc.(NASDAQ:ACAD) stock jumped 4.72% and closed at $2.22 in the last trading session. The company last week said that it has completed enrollment of its latest Phase 3 Pimavanserin trial, dubbed the -020 study. Pimavanserin is an oral treatment for Parkinson’s Disease Psychosis, for which there is no FDA approved treatment available in the U.S.
How Should Investors React To ACAD Now? Find Out Here
Beststocksdaily.com team is engaged in providing valuable and updated news information on U.S. stocks on a regular basis. Beststocksdaily.com instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. To Get Instant updates in the inbox, readers are advised to sign up for free at Beststocksdaily.com.
The assembled information disseminated by beststocksdaily.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. beststocksdaily.com does expect that investors will buy and sell securities based on information assembled and presented in beststocksdaily.com. PLEASE always do your own due diligence, and consult your financial advisor.
- Head Lice 101′ Program Introduced At Chicago Area Schools
- DS Healthcare Announces Results from New Clinical Study
- WILLS EYE HOSPITAL ADVANCES TO #2 BEST IN NATION FOR OPHTHALMOLOGY
- Paediatric First Aid Courses Gain County Council Approval
- Amen Clinics, Inc. Appoint Highly-Acclaimed Robert R. Johnson, D.O. to National Medical Director